Rurioctocog alfa pegol

Drug Profile

Rurioctocog alfa pegol

Alternative Names: Adynovate; Adynovi; Antihemophilic Factor (Recombinant), PEGylated - Shire; BAX-855; EHL rFVIII PEG; Extended half-life recombinant FVIII; Full-length longer-acting rFVIII; LA rFVIII PEG; PEG factor VIII - Shire; PEGylated recombinant factor VIII; PEGylated rFVIII

Latest Information Update: 01 Feb 2017

Price : $50

At a glance

  • Originator Baxter International; Nektar Therapeutics
  • Developer Shire
  • Class Antihaemorrhagics; Blood coagulation factors; Polyethylene glycols; Recombinant proteins
  • Mechanism of Action Blood coagulation factor replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Haemophilia A

Most Recent Events

  • 28 Dec 2016 Launched for Haemophilia A (In children, In infants, In neonates, Treatment-experienced) in USA (IV)
  • 28 Dec 2016 Launched for treatment of patients with Haemophilia A (In adolescents, In adults) in surgical settings in USA
  • 27 Dec 2016 Registered for Haemophilia A (In children, In infants, In neonates, Treatment-experienced) in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top